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Abstract
Background Surgical profundaplasty (SP)is used mainly
as an adjunct to endovascular management of peripheral
vascular disease (PAD) today. Results from earlier series of
profundaplasty alone have been controversial, especially
regarding its hemodynamic effect. The question is: Can
profundaplasty alone still be useful? Our aim was to
evaluate its role in the modern management of vascular
patients.
Methods This was a retrospective outcome study. A
consecutive series of 97 patients (106 legs) from January
2000 through December 2003 were included. In 55 (52%)
legs, the superficial femoral artery was occluded. These
patients were included in the current analysis. Of these
patients 14 (25%) were female. Mean age was 71 ((11)
years. Nineteen (35%) were diabetic. The indication for
operation was claudication in 29 (53%), critical leg
ischemia (CLI) in 26 (47%), either with rest pain in 17
(31%), or ulcer/gangrene in 9 (16%). Endarterectomy with
patch angioplasty with bovine pericardium was performed
in all cases. Mean follow-up was 33 ( 14 months. Mean
preoperative ankle brachial index (ABI) was 0.6. Sustained
clinical efficacy was defined as upward shift of 1 or greater
on the Rutherford scale without repeat target limb revas-
cularization (TLR) or amputation. Mortality, morbidity,
need for TLR, or amputation were separate endpoints.
Results Postoperatively, ABI was significantly improved
(mean = 0.7), in 24 (44%) by more than 0.15. At three
years, cumulative clinical success rate was 80%. Overall,
patients with claudication had a better outcome than those
with CLI (p = 0.04). Two (4%) major amputations and 2
(4%) minor ones were performed, all in patients with CLI.
None of the 9 (16%) ulcers healed.
Conclusion Profundaplasty is still a valuable option for
patients with femoral PAD and claudication without tissue
loss. It is a straightforward procedure that combines good
efficacy with low complication rates. Further endovascular
treatment may be facilitated. It is not useful for patients
with the combination of critical ischemia and tissue loss.
Since the introduction of distal surgical revascularization
and later catheter-based management, surgical profun-
daplasty is not commonly performed anymore. Results
from earlier clinical series have been controversial. In a
recent review, Earnshaw [1] concluded: ‘‘There is little
literature and no science to provide clear recommendations
for profunda disease. Indeed, the TransAtlantic Inter-
Society Consensus has nothing to say on the subject.’’
Calcified femoral arterial bifurcation is not readily acces-
sible for the interventionalist either. A profundaplasty is a
straightforward procedure with low morbidity and short
hospital stay. Does it have any role at all in vascular sur-
gery, or should it simply become part of medical history?
The aim of our study was to clarify the outcome following
open surgical profundaplasty in modern practice.
Methods
Between January 2000 and December 2003, 106 profun-
daplasties were performed in 97 patients at the Swiss
Cardiovascular Center (SCVC) in Berne, Switzerland. Of
the 97 patients, 14 (25%) were female. Mean age was 71
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(±11) years.The superficial femoral artery (SFA) was oc-
cluded in 55 (52%) cases. These patients were included in
the study. Patient charts were retrospectively reviewed.
Patient characteristics are seen in Table 1.
Indication for operation was lifestyle-limiting claudica-
tion in 29 (53%) and CLI in 26 (47%) patients, of which 9
(16%) had ulcer or tissue loss. Preoperative duplex scan
and angiography were obtained. Mean preoperative ABI
was 0.6.
Patient selection criteria included (1) severe stenosis of
femoral bifurcation, especially of common and proximal
profunda femoris artery with occlusion of the superficial
femoral artery, (2) adequate proximal inflow or inflow to be
improved by PTA/stenting, and (3) collaterals seen in
angiography. Tibial runoff was not an exclusion criteria.
The operations were performed as primary surgical
reconstruction. Previous PTA and/or stenting had been
performed 27 times in 16 (29%) patients (iliac artery 6,
common femoral 2, superficial femoral 14, profunda fem-
oris 1, popliteal 4 times). Profundaplasty was performed as
previously described by Martin et al. [2]. Arterial closure
was done using bovine pericardial patch (Vascu-guard,
Synovis Life Technologies Inc., St Paul, MN) in all cases.
Mean (±SD) follow-up was 33 (±14.5) months. Sustained
clinical treatment efficacy was defined as an upward shift
of one or more on the Rutherford scale [3] without repeat
target limb revascularization (TLR) or amputation. Mor-
tality, need of amputation, or repeat TLR were solitary
study endpoints. Cumulative freedom from surgical rein-
tervention was defined as freedom from minor or major
amputation or arterial reconstruction. Subgroup analysis
was performed for Fontaine stages, for isolated (IP) or
combined (IP with PTA or stenting) procedure, and dia-
betes mellitus. Ankle brachial pressure index (ABPI) was
measured at baseline and postoperatively at intervals. All
patients were followed up in the Department of Angiology
at the SCVC.
Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS Inc., Chicago, IL). Preoperative factors predicting
successful outcome were analyzed using Fischer’s exact
test. Kaplan–Meier survival analysis was used to estimate
the rates of cumulative freedom from surgical reinterven-
tion and sustained clinical treatment efficacy. Statistical
significance of observed differences were evaluated by the
log-rank test. Wilcoxon signed-rank test was used to
compare ABPI before and after revascularization.
Results
Patients were followed at the Swiss Cardiovascular Centre
at three and six months and then annually by clinical
examination, ABPI measurement, and duplex scan to en-
sure the patency of the profunda femoris artery. There was
no 30-day mortality in the group of claudicants, but
two patients (4%) with extreme critical ischemia died
postoperatively from myocardial infarction. Perioperative
complications are seen in Table 2. Minor surgical com-
plications occurred in five (9%) cases: one (2%) superficial
infection and three (4%) postoperative hematomas were
surgically evacuated under local anesthesia. One (2%)
developed postoperative pneumonia. Mean postoperative
ABPI was 0.7. in 24 (44%) patients; it improved signifi-
cantly (>0.15) after profundaplasty. The difference in pre-
versus postoperative ABPI was less than 0.05.
Sustained clinical treatment efficacy according to
Rutherford [3] was 80% at three years (Fig. 1). In five (9%)
legs, a femoropopliteal reconstruction was performed
during follow-up (2 in claudicants, 3 for critical limb
ischemia). In five (9%) legs, an occlusion of SFA was
postoperatively treated by PTA at an average of five
months after the initial procedure. Two (4%) iliac arteries
were stented to improve inflow. TLRs included two (4%)
PTAs of the distal profunda. The overall TLR rate was 10
(18%), with some arteries undergoing more than one PTA.
Cumulative freedom from surgical reintervention was
84% at three years. There was a difference between clau-
Table 1 Patient characteristics
Age (mean, yr) 71 ± 11
Female 14 (25%)
Male 41 (75%)
Fontaine II 29 (53%)
Fontaine III 17 (31%)
Fontaine IV 9 (16%)
Smoking 41 (75%)
Diabetes mellitus 19 (35%)
Renal insufficiency 11 (20%)
Obesity 14 (25%)
Dyslipidemia 23 (42%)
Hypertension 38 (69%)
COPD 12 (22%)
COPD = chronic obstructive pulmonary disease, renal insuffi-
ciency = creatinine > 140 mg/ml, dyslipidemia = under treatment
with statins, obesity = body mass index > 30 kg/m2
Table 2 Perioperative morbidity
Hematoma 3 (6%)
Wound infection 1 (2%)
Myocardial infarction 2 (4%)
Pneumonia 1 (1%)
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dicants (2, 7%) and patients with CLI (5, 19%). Clinically,
subgroup analysis showed an upward shift in the Ruther-
ford classification in claudicants versus CLI. Healing of
ischemic lesions was not seen in any of the nine (17%)
legs. In the remaining ones, two (4%) major and two (4%)
minor amputations were performed.
Discussion
Profundaplasty alone is not commonly performed anymore.
It has been replaced by vascular reconstructions and cath-
eter-based interventions. The inevitable question today is:
Does surgical profundaplasty have any role in the modern
management of peripheral vascular disease?
The surgical importance of the profunda femoris artery
was discussed by Morris et al. [4] and Leeds et al. [5] in the
early 1960s. The revascularization of the deep femoral
artery to treat peripheral arterial occlusive disease was
introduced by Natali in 1962 [6]. Cotton and Roberts [7]
popularized the deep extended profundaplasty in the 1960s.
Martin and Bouhoutsos [8] favored a patch over a short
length. The first series was published by Martin and
Bouhoutsos [8], but it dealt mainly with proximal inflow
procedures. Jamieson [9] declared that profundaplasty
should be used to treat only critical ischemia and was not
indicated when the superficial femoral artery is patent. In
our unit, we knowingly apply it to patients with claudica-
tion, thinking of it rather as part of general management
than as a last resort prior to amputation. In our unit, pro-
fundaplasty is performed in patients with a patent superfi-
cial femoral artery (47%) and in patients with an occluded
superficial femoral artery (53%). It has been compared to
femoropopliteal reconstructions as well [10]. To clarify the
effect of profundaplasty alone, we excluded patients with a
patent SFA from the analysis.
Many opponents of profundaplasty think it has a very
limited hemodynamic effect [11–13]. However, in our
study there was a significant postoperative increase in ABI
(mean = 0.6–0.7). Of the 97 patients, 44% had an
improvement of greater than 0.15 compared with their
preoperative values.
Clinical improvement after profundaplasty has been
reported [14–16], but generally the results have been
controversial: Rollins et al. [17] reported healing of ulcers
in 53% in a small series. Cotton and Roberts [7] reported
success in 59%, treating 68 patients with severe claudica-
tion, rest pain, and ulcers. Fugger et al. [11] reported
improvement in 38% in Fontaine stage III ischemia and
28% in IV. Amputations could not be avoided. Our group
has compared the results of surgical profundaplasty to
those of PTA [18]. In our study profunda revascularization
was not sufficient in Fontaine class IV ischemia (healing in
none of the of 9 cases), but it was beneficial in patients with
rest pain.
In our series, nine (17%) PTAs were performed within
one year of the operation. Interestingly, five (9%) of our
patients had a PTA of their SFA, probably due to the
introduction of modern advanced guidewires that started
appearing during the study period. In this situation the
patch may well facilitate access for the intervention. In our
series, bovine pericardial patch was used in all cases,
leaving the vein intact for further options. One (2%)
superficial infection was seen. Miksic and Novak [19] re-
ported impaired results in connection with PTA/stenting of
the iliac artery. In our series, PTA/stenting of the iliac
artery was performed in 18% to improve inflow.
In our series, profundaplasty showed a cumulative rate
of freedom from any surgical revascularization in 80% at
three years, which can be compared to the results of Sutter
et al. [15], who showed a 75% rate at five years in patients
with Fontaine stage II. Sustained clinical treatment efficacy
was 80% at three years, which compares favorably with the
results of Jamil et al. [12], who found a 35% success rate in
a mixed series of patients.
Patients with critical ischemia may benefit from pro-
fundaplasty as well. However, in the nine patients with CLI
and tissue loss, none of the ulcers healed. Conceivably, all
amputations were performed in this group. Similar results
have been reported by Miksic and Novak [19]. CLI with
time in months
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Fig. 1 Kaplan–Meier analysis for sustained clinical efficacy accord-
ing to Rutherford et al. [3]
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tissue loss can be seen as an indication for femoropoliteal
reconstruction, as reported by Martin and Bouhoutsos [8].
Remote superficial artery endarterectomy and distal
stenting have been reported by Rosenthal et al. [20] with a
primary patency rate of 60% at 33 months. The procedure
includes femoral endarterectomy if needed. We have no
experience with the technique described by Moll et al. [21],
but obviously it is technically more demanding than pro-
fundaplasty alone.
In our study, a short hospital stay and a low rate of
complications (no mortality or major morbidity in patients
with claudication) were seen. Amputations and mortality
were restricted to patients with catastrophic critical ische-
mia without any possibility of surgical revascularization.
As such, profundaplasty does not mean difficulties in case
vascular reconstruction is later needed, and the vein is left
intact. The bovine pericardial patch is easy to access sur-
gically, and it can readily be punctured for endovascular
interventions.
Limitations of our study include its retrospective nature
and its relatively small number of patients. However, our
follow-up coverage was good and the results present proof
of concept for the procedure.
In conclusion, profundaplasty, either alone or combined
with proximal or distal endovascular intervention, can be
used in selected patients suffering from claudication or
critical ischemia. It brings good relief of symptoms and
objectively improves distal circulation. The operation is
straightforward and can be performed with short hospital-
ization and low complication rates. Profundaplasty is use-
ful in critical ischemia with rest pain, but it should not be
performed in patients with ischemic tissue loss.
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